CN103755710A - 一类2,5-二氮杂双环庚烷类化合物及其应用 - Google Patents
一类2,5-二氮杂双环庚烷类化合物及其应用 Download PDFInfo
- Publication number
- CN103755710A CN103755710A CN201410014704.4A CN201410014704A CN103755710A CN 103755710 A CN103755710 A CN 103755710A CN 201410014704 A CN201410014704 A CN 201410014704A CN 103755710 A CN103755710 A CN 103755710A
- Authority
- CN
- China
- Prior art keywords
- diazabicyclo
- heptane
- carbonyl
- group
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2,5-diazabicyclo heptane compound Chemical class 0.000 title claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 125000002837 carbocyclic group Chemical group 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000005936 piperidyl group Chemical group 0.000 claims description 4
- UKHJNJFJCGBKSF-UHFFFAOYSA-N 2,5-diazabicyclo[2.2.1]heptane Chemical compound C1NC2CNC1C2 UKHJNJFJCGBKSF-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000004806 1-methylethylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 125000006017 1-propenyl group Chemical group 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- YUOOVCZCRIGPOX-HTRCEHHLSA-N CC(N(C[C@@H](C1)N2)[C@H]1C2=C=O)=O Chemical compound CC(N(C[C@@H](C1)N2)[C@H]1C2=C=O)=O YUOOVCZCRIGPOX-HTRCEHHLSA-N 0.000 claims description 2
- RRJOKEPXASTBAY-HTRCEHHLSA-N CCC(N(C[C@@H](C1)N2)[C@H]1C2=C=O)=O Chemical compound CCC(N(C[C@@H](C1)N2)[C@H]1C2=C=O)=O RRJOKEPXASTBAY-HTRCEHHLSA-N 0.000 claims description 2
- JHFRNLBJQAVOAG-HTRCEHHLSA-N CCN(C[C@@H](C1)N2)[C@H]1C2=C=O Chemical compound CCN(C[C@@H](C1)N2)[C@H]1C2=C=O JHFRNLBJQAVOAG-HTRCEHHLSA-N 0.000 claims description 2
- WCHOTYAOTGSYNK-IYSWYEEDSA-N CN(C[C@@H](C1)N2)[C@H]1C2=C=O Chemical compound CN(C[C@@H](C1)N2)[C@H]1C2=C=O WCHOTYAOTGSYNK-IYSWYEEDSA-N 0.000 claims description 2
- NZWISZXXSPIXHK-ZWNOBZJWSA-N C[C@@](C[C@H](C1)N2)(C2=C=O)N1C1CCCCC1 Chemical compound C[C@@](C[C@H](C1)N2)(C2=C=O)N1C1CCCCC1 NZWISZXXSPIXHK-ZWNOBZJWSA-N 0.000 claims description 2
- IAWPENRVNONIKY-UHFFFAOYSA-N O=C(C1(C2)NCC2NC1=C=O)C1=CC=CC=C1 Chemical compound O=C(C1(C2)NCC2NC1=C=O)C1=CC=CC=C1 IAWPENRVNONIKY-UHFFFAOYSA-N 0.000 claims description 2
- WWYPLYYCTQDIKZ-ZYHUDNBSSA-N O=C(C1=CC=CC=C1)N(C[C@@H](C1)N2)[C@H]1C2=C=O Chemical compound O=C(C1=CC=CC=C1)N(C[C@@H](C1)N2)[C@H]1C2=C=O WWYPLYYCTQDIKZ-ZYHUDNBSSA-N 0.000 claims description 2
- LQEGLDUHWOSZSU-ZYHUDNBSSA-N O=C(C1CCCCC1)N(C[C@@H](C1)N2)[C@H]1C2=C=O Chemical compound O=C(C1CCCCC1)N(C[C@@H](C1)N2)[C@H]1C2=C=O LQEGLDUHWOSZSU-ZYHUDNBSSA-N 0.000 claims description 2
- HPFNZLBNZKLHEG-BXKDBHETSA-N O=C=C([C@H]1C2)N[C@H]2CN1C1CCCCC1 Chemical compound O=C=C([C@H]1C2)N[C@H]2CN1C1CCCCC1 HPFNZLBNZKLHEG-BXKDBHETSA-N 0.000 claims description 2
- WABXBWOGWSTOSO-CRAIPNDOSA-N O=C=C([C@H]1C2)N[C@H]2CN1C1CCN(CC2=CC=CC=C2)CC1 Chemical compound O=C=C([C@H]1C2)N[C@H]2CN1C1CCN(CC2=CC=CC=C2)CC1 WABXBWOGWSTOSO-CRAIPNDOSA-N 0.000 claims description 2
- QGURVXXAPSXQPM-IFJNFQAOSA-N O=C=C([C@H]1C2)N[C@H]2CN1C1CN(CC2=CC=CC=C2)CCC1 Chemical compound O=C=C([C@H]1C2)N[C@H]2CN1C1CN(CC2=CC=CC=C2)CCC1 QGURVXXAPSXQPM-IFJNFQAOSA-N 0.000 claims description 2
- YAFZKUDQGQDRSJ-LDYMZIIASA-N O=C=C1N[C@H]2CN(C3CCCC3)[C@@H]1C2 Chemical compound O=C=C1N[C@H]2CN(C3CCCC3)[C@@H]1C2 YAFZKUDQGQDRSJ-LDYMZIIASA-N 0.000 claims description 2
- PWUBOOIGKHGQFI-DGCLKSJQSA-N O=C=C1N[C@H]2CN(CC3=CC=CC=C3)[C@@H]1C2 Chemical compound O=C=C1N[C@H]2CN(CC3=CC=CC=C3)[C@@H]1C2 PWUBOOIGKHGQFI-DGCLKSJQSA-N 0.000 claims description 2
- IZGJEYUVAMUKNZ-RFZPGFLSSA-N O=C=C1N[C@H]2CN[C@@H]1C2 Chemical compound O=C=C1N[C@H]2CN[C@@H]1C2 IZGJEYUVAMUKNZ-RFZPGFLSSA-N 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 238000010189 synthetic method Methods 0.000 abstract description 11
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract 1
- 150000003951 lactams Chemical class 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 56
- 238000002360 preparation method Methods 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000001035 drying Methods 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- 238000001914 filtration Methods 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 15
- 239000012266 salt solution Substances 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- 239000012043 crude product Substances 0.000 description 14
- 238000000605 extraction Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 238000001816 cooling Methods 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 0 *NCC(C*=C1)NC1O Chemical compound *NCC(C*=C1)NC1O 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 238000010025 steaming Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VTUQEDLGFFKEDV-DTIOYNMSSA-N COC(=O)[C@@H]1CC(CN1C(=O)C2=CC=CC=C2)N Chemical class COC(=O)[C@@H]1CC(CN1C(=O)C2=CC=CC=C2)N VTUQEDLGFFKEDV-DTIOYNMSSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- XNBGBNPWRPCGBA-WBVHZDCISA-N methyl (2S,4R)-4-amino-1-(1-benzylpiperidin-4-yl)pyrrolidine-2-carboxylate Chemical class COC(=O)[C@@H]1C[C@H](CN1C2CCN(CC2)CC3=CC=CC=C3)N XNBGBNPWRPCGBA-WBVHZDCISA-N 0.000 description 2
- VTUQEDLGFFKEDV-MNOVXSKESA-N methyl (2S,4R)-4-amino-1-benzoylpyrrolidine-2-carboxylate Chemical class COC([C@H]1N(C[C@@H](C1)N)C(C1=CC=CC=C1)=O)=O VTUQEDLGFFKEDV-MNOVXSKESA-N 0.000 description 2
- DROVTANONRBMRA-NEPJUHHUSA-N methyl (2S,4R)-4-amino-1-benzylpyrrolidine-2-carboxylate Chemical class COC([C@H]1N(C[C@@H](C1)N)CC1=CC=CC=C1)=O DROVTANONRBMRA-NEPJUHHUSA-N 0.000 description 2
- DVACAGKCJRNNTD-KOLCDFICSA-N methyl (2S,4R)-4-amino-1-cyclohexylpyrrolidine-2-carboxylate Chemical class COC(=O)[C@@H]1C[C@H](CN1C2CCCCC2)N DVACAGKCJRNNTD-KOLCDFICSA-N 0.000 description 2
- MSYDJEJTQXSRBR-RQJHMYQMSA-N methyl (2s,4r)-1-acetyl-4-aminopyrrolidine-2-carboxylate Chemical class COC(=O)[C@@H]1C[C@@H](N)CN1C(C)=O MSYDJEJTQXSRBR-RQJHMYQMSA-N 0.000 description 2
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- MFPWEWYKQYMWRO-UHFFFAOYSA-N tert-butyl carboxy carbonate Chemical compound CC(C)(C)OC(=O)OC(O)=O MFPWEWYKQYMWRO-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BSDZDBHWJWLKBN-LHHJGKSTSA-N CC1C(C/C=C(/CN(CC(CC2)N)C2C(C)=O)\C#C)=C1 Chemical compound CC1C(C/C=C(/CN(CC(CC2)N)C2C(C)=O)\C#C)=C1 BSDZDBHWJWLKBN-LHHJGKSTSA-N 0.000 description 1
- RDTCWQXQLWFJGY-RXMQYKEDSA-N CC[C@H](CNC)O Chemical compound CC[C@H](CNC)O RDTCWQXQLWFJGY-RXMQYKEDSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- RKEYKDXXZCICFZ-UHNVWZDZSA-N O[C@H](CC1)CN[C@@H]1C(O)=O Chemical compound O[C@H](CC1)CN[C@@H]1C(O)=O RKEYKDXXZCICFZ-UHNVWZDZSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000003567 TRPV4 Human genes 0.000 description 1
- 101150098315 TRPV4 gene Proteins 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 235000015177 dried meat Nutrition 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003845 household chemical Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000007273 lactonization reaction Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- JYJKFDHLEYMLDX-NEPJUHHUSA-N methyl (2s,4r)-1-benzyl-4-hydroxypyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1C[C@@H](O)CN1CC1=CC=CC=C1 JYJKFDHLEYMLDX-NEPJUHHUSA-N 0.000 description 1
- ZORHSASAYVIBLY-UHNVWZDZSA-N methyl (2s,4r)-4-hydroxypyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1C[C@@H](O)CN1 ZORHSASAYVIBLY-UHNVWZDZSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000005054 naphthyridines Chemical class 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 108010021724 tonin Proteins 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本发明公开了属于化学合成技术领域的一类新型合成中间体2,5-二氮杂双环庚烷类化合物,即一类新的双环内酰胺药物中间体(1R,4R)-2-取代-6-羰基-2,5-二氮杂双环[2.2.1]庚烷类化合物,及其合成方法,本发明提供的化合物可应用于(1R,4R)-2,5-二氮杂双环[2.2.1]庚烷及其衍生物的合成,且步骤少、合成效率高,适用于产业化生产。
Description
技术领域
本发明属于化学合成技术领域,特别涉及一类新型2,5-二氮杂双环庚烷类化合物,具体是指(1R,4R)-2-取代-6-羰基-2,5-二氮杂双环[2.2.1]庚烷,此类化合物可作为合成中间体,应用于药物、材料、农用化学品、精细化学品、日用化学品等领域。
背景技术
2,5-二氮杂双环[2.2.1]庚烷(2,5-diazabicyclo[2.2.1]heptane, DABCH)及其衍生物是一类重要的药物合成中间体。例如,专利WO 2011/054922公布了一类含有DABCH结构片段的抗风湿性关节炎药物,专利WO 2010/011912和WO 2009/111680公布了一类含有DABCH结构片段的阳离子通道TRPV4拮抗剂,专利WO 2009/137503公布了一类含有DABCH结构片段的组蛋白去乙酰化酶抑制剂,专利WO 2009/063364公布了一类含有DABCH结构片段的紧张肽受体抑制剂,专利CN 2010/102167700和CN 2010/102167702公布了一类含有三氟甲基取代的DABCH衍生物及其制备方法。文献报道中,DABCH及其衍生物在抗生素 [1-4]、降血压药 [3, 5]、止痛药 [6] 等药物化学研究领域,以及在不对称催化 [7,8] 等方面也有广泛的应用。
DABCH有两个对映异构体,即(1S,4S)-和(1R,4R)-异构体,均从易得的天然氨基酸L-羟脯氨酸(反式-4-羟基-L-脯氨酸,(2S,4R)-4-羟基脯氨酸,1)出发制备。其中,(1S,4S)-异构体的制备较为便捷,而(1R,4R)-异构体的制备较为繁琐,需要对L-羟脯酸的2位和4位两个手性中心进行构型翻转。专利CN 2010/102167700对(1R,4R)-DABCH的现有合成方法 [2,7] 进行了总结,首先利用内酯化反应翻转2位构型,再经亲核取代反应翻转4位构型,最后经还原、磺酸酯化和胺基化关环反应获得(1R,4R)-DABCH结构(见以下反应结构式)。然而,这一合成方法的路线较长,共需9步反应,导致(1R,4R)-DABCH及其衍生物较难获得,限制了在化学合成和药物研究中的应用。
基于我们的前期研究,本发明的目的是提供一种从L-羟脯氨酸衍生物(2S,4R)-1-取代-4-胺基-L-脯氨酸 [8,9] 出发制得的新型化合物,即(1R,4R)-2-取代-6-羰基-2,5-二氮杂双环[2.2.1]庚烷。以其为合成中间体,能够以更短的路线合成(1R,4R)-DABCH及其衍生物。
参考文献
[1] Rosen, T., Chu, D. T. W., Lico, I. M., Fernandes, P. B., Marsh, K., Shen, L., Cepa, V. G., Pernet, A. G. Design, synthesis, and properties of (4S)-7-(4-amino-2-substituted-pyrrolidin-l- yl)quinolone-3-carboxylic acids. J. Med. Chem. 1988, 31, 1598-1611.
[2] Bouzard, D., Di Cesare, P., Essiz, M., Jacquet, J. P., Kiechel, J. R., Remuzon, P., Weber, A., Oki, T., Masuyoshi, M., Kessler, R. E., Fung-Tomc, J., Desiderio, J. Fluoronaphthyridines and quinolones as antibacterial agents. 2. Synthesis and structure-activity relationships of new 1-tert-butyl 7-substituted derivatives. J. Med. Chem. 1990, 33, 1344-1352.
[3] Remuzon, P., Bouzard, D., Guiol, C., Jacquet, J.-P. Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(1-, 3-, 4-, and 6-methyl-2,5-diazabicyclo[2.2.1]heptan-2-y1) naphthyridine analogues of 7-[(1R,4R)-2,5- diazabicyclo[2.2.1]heptan-2-yl]-1-(1,1-dimethylethyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid. Influence of the configuration on blood pressure in dogs. A quinolone-class effect. J. Med. Chem. 1992, 35, 2898-2909.
[4] Huang, X. G., Chen, D. L., Wu, N., Zhang, A. Q., Jia, Z. H., Li, X. S. The synthesis and biological evaluation of a novel series of C7 non-basic substituted fluoroquinolones as antibacterial agents. Bioorg. Med. Chem. Lett. 2009, 19, 4130-4133.
[5] Hughes, R. O., Rogier, D. J., Jacobsen, E. J., Walker, J. K., MacInnes, A., Bond, B. R., Zhang, L. L., Yu, Y., Zheng, Y., Rumsey, J. M., Walgren, J. L., Curtiss, S. W., Fobian, Y. M., Heasley, S. E., Cubbage, J. W., Moon, J. B., Brown, W. L., Acker, B. A., Maddux, T. M., Tollefson, M. B., Mischke, B. V., Owen, D. R., Freskos, J. N., Molyneaux, J. M., Benson, A. G., Blevis-Bal, R. M. Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin- 1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5). J. Med. Chem. 2010, 53, 2656-2660.
[6] Bunnelle, W. H., Daanen, J. F., Ryther, K. B., Schrimpf, M. R., Dart, M. J., Gelain, A., Meyer, M. D., Frost, J. M., Anderson, D. J., Buckley, M., Curzon, P., Cao, Y. J., Puttfarcken, P., Searle, X., Ji, J. G., Putman, C. B., Surowy, C., Toma, L., Barlocco, D. Structure-activity studies and analgesic efficacy of N-(3-pyridinyl)-bridged bicyclic diamines, exceptionally potent agonists at nicotinic acetylcholine receptors. J. Med. Chem. 2007, 50, 3627-3644.
[7] Melgar-Fernández, R. et al., Synthesis of novel derivatives of (1S,4S)-2,5-diazabicyclo[2.2.1] heptane and their evaluation as potential ligands in asymmetric catalysis. Eur. J. Org. Chem. 2008: 655-672.
[8] Jordis, U. et al., New C-substituted (1S,4S)-2,5-diazabicyclo[2.2.1]heptane derivatives. Preparation utilizing the directed metalation strategy. Application in enantioselective catalysis. Arkivoc 2001: 69-81.
[9] Baker, G. L., Fritschel, S. J., Stille, J. R., Stille, J. K. Transition metal catalyzed asymmetric organic synthesis via polymer-attached optically active phosphine ligands. 5. Preparation of amino acids in high optical yield via catalytic hydrogenation. J. Org. Chem. 1981, 46, 2954-2960。
发明内容
本发明的目的在于提供一类新的2,5-二氮杂双环庚烷类化合物,即一类新的双环内酰胺药物中间体(1R,4R)-2-取代-6-羰基-2,5-二氮杂双环[2.2.1]庚烷类化合物((1R,4R)-2-取代-6-羰基-DABCH),该化合物(1R,4R)-2-取代-6-羰基-DABCH具有通式I的化学结构:
式中:
(1) R可为-R1、-C(=O)R2或-C(=O)OR3;
(2) R1为氢,或C1-C15的饱和或不饱和的取代基(可含碳环或杂环、或含直链或支侧链、或含杂原子取代基);
(3) R2为氢,或C1-C15的饱和、不饱和或芳香的取代基(可含碳环或杂环、或含直链或支侧链、或含杂原子取代基);
(4) R3为C1-C15的饱和、不饱和或芳香的取代基(可含碳环或杂环、或含直链或支侧链、或含杂原子取代基)。
本发明中所述R1为氢、甲基、乙基、丙基、异丙基、丁基、叔丁基、戊基、环戊基、己基、环己基、庚基、环己基甲基、辛基、壬基、癸基、烯丙基、苄基、4-甲氧基苄基、3-氟苄基、3-氯苄基、4-(1-苄基)哌啶基、3-(1-苄基)哌啶基。
本发明中所述R2为氢、甲基、乙基、丙基、异丙基、丁基、叔丁基、戊基、环戊基、己基、环己基、庚基、环己甲基、辛基、壬基、癸基、苯基、4-甲氧基苯基、3-氟苯基、3-氯苯基、乙烯基、1-甲基乙烯基、1-丙烯基、环戊基、环己基、2-噻吩基、3-噻吩基、2-吡啶基、3-吡啶基、4-吡啶基。
本发明中所述R3为苄基、4-甲氧基苄基、4-氯苄基、甲基、乙基、丙基、丁基、叔丁基、烯丙基、环己基、苯基。
优选的本发明化合物包括:
(1)(1R,4R)-3-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(2)(1R,4R)-2-甲基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(3)(1R,4R)-2-乙基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(4)(1R,4R)-2-丙基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(5)(1R,4R)-2-环戊基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(6)(1R,4R)-2-环己基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(7)(1R,4R)-2-环己基甲基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(8)(1R,4R)-2-(1-苄基-4-哌啶基)-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(9)(1R,4R)-2-(1-苄基-3-哌啶基)-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(10)(1R,4R)-2-烯丙基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(11)(1R,4R)-2-苄基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(12)(1R,4R)-2-甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(13)(1R,4R)-2-乙酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(14)(1R,4R)-2-丙酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(15)(1R,4R)-2-特戊酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(16)(1R,4R)-2-环戊甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(17)(1R,4R)-2-环己甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(18)(1R,4R)-2-苯甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(19)(1R,4R)-2-(4-甲氧基)苯甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(20)(1R,4R)-2-(甲氧基)甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(21)(1R,4R)-2-(乙氧基)甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(22)(1R,4R)-2-(烯丙氧基)甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(23)(1R,4R)-2-(苄氧基)甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(24)(1R,4R)-2-(叔丁氧基)甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷。
本发明中双环内酰胺(1R,4R)-2-取代-6-羰基-DABCH类化合物的合成采用L-羟脯氨酸(1)为原料,通过Jordis等和Baker等报道的方法,得到(2S,4R)-1-取代-4-氨基脯氨酸酯(通式A),后者在强碱(如甲醇钠、叔丁醇钾、KHMDS或LDA)的作用下,发生2位消旋化和分子内酯胺解串联反应,形成双环内酰胺(1R,4R)-2-取代-6-羰基-DABCH(通式B)。
其中:R4为甲基、乙基、丙基、异丙基、叔丁基或苯基等;R如前所述。
(1R,4R)-2-取代-6-羰基-DABCH(B)可经酰胺还原试剂如氢化锂铝或硼烷等作用,得到(1R,4R)-DABCH衍生物,并通过已知官能团转换方法得到 (1R,4R)-DABCH的其它衍生物。例如(1R,4R)-2-苯甲酰基-6-羰基-DABCH(4)的如下转化:
本发明提供的中间体(1R,4R)-2-取代-6-羰基-DABCH可用于制备(1R,4R)-DABCH及其衍生物,由于步骤较少,可有效提高合成效率,适用于(1R,4R)-DABCH及其衍生物的产业化生产,应用于药物研究和化学合成领域。
具体实施方式
以下通过实施例对本发明作进一步详细说明,但本发明的保护范围不局限于所述内容。
实施例1:(1R,4R)-2-苯甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备,具体内容如下:
(1)(2S,4R)-1-苯甲酰基-4-羟基脯氨酸的制备
L-羟基脯氨酸(0.50 g,3.81 mmol)加入水(2.0 ml)中,冰浴冷却下加入NaOH水溶液(25%,0.61 g,3.81 mmol),随后缓慢滴加苯甲酰氯(0.96 g,6.86 mmol),滴加过程中加入NaOH水溶液控制pH为9,反应完全后,加入盐酸调节pH到2,氯仿萃取,无水硫酸镁干燥,过滤,浓缩得白色固体粉末0.70 g,产率78%。
(2)(2S,4S)-1-苯甲酰基-4-羟基脯氨酸甲酯的制备
(2S,4R)-1-苯甲酰基-4-羟基脯氨酸(2.50 g,10.6 mmol)溶于二氯甲烷(25 ml),冰浴冷却下加入吡啶(2.5 g,31.6 mmol),缓慢滴加甲基磺酰氯(3.00 g,26.2 mmol),反应完毕后,加水淬灭,分出有机层,水相用二氯甲烷萃取,合并有机相,依次用水、食盐水洗涤,无水硫酸镁干燥,过滤浓缩,得类白色固体;将此固体溶于无水甲醇(40 ml)中,冰浴冷却下加入氯化氢甲醇溶液(17.8%,15.2 g),反应完毕后,减压蒸除甲醇,加入二氯甲烷和水,分出有机层,水层以二氯甲烷萃取两次,合并有机相,饱和食盐水洗涤,无水硫酸镁干燥,过滤,浓缩,粗产物经硅胶柱层析纯化(石油醚-乙酸乙酯)得白色固体1.57 g,产率59%。
(3)(2S,4R)-1-苯甲酰基-4-叠氮基脯氨酸甲酯的制备
(2S,4S)-1-苯甲酰基-4-羟基脯氨酸甲酯(3.00 g,12.0 mmol)溶于二氯甲烷(40 ml)中,冰浴冷却下加入三乙胺(5.1 ml, 36.6 mmol),慢慢滴加甲基磺酰氯(2.8 ml,36.2 mmol),反应完毕后加水淬灭,分出有机层,水相用二氯甲烷萃取,合并有机相,食盐水洗涤,无水硫酸镁干燥,过滤浓缩,得微黄色固体;将此固体溶于无水DMF(40 ml)中,加入叠氮化钠(3.9 g,60 mmol),在70℃搅拌7 h,降至室温,加水淬灭;乙酸乙酯-石油醚(v/v 2:1)混合液萃取,用水、食盐水依次洗涤,无水硫酸镁干燥,过滤浓缩。粗产物经硅胶柱层析(石油醚-乙酸乙酯)纯化,得无色油状物3.00 g,产率91%。
(4)(2S,4R)-1-苯甲酰基-4-氨基脯氨酸甲酯的制备
(2S,4R)-1-苯甲酰基-4-叠氮基脯氨酸甲酯(3.00 g,10.9mmol)溶于甲醇(200 ml)中,加入10% Pd/C(0.30 g),通入氢气(1 atm),室温反应3 h,硅藻土过滤,浓缩,粗产物经硅胶柱层析(甲醇-乙酸乙酯)纯化,得无色油状物2.61 g,产率96%。
(5)(1R,4R)-2-苯甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
氮气保护下,将(2S,4R)-1-苯甲酰基-4-氨基脯氨酸甲酯(0.25 g,1.0 mmol)溶于无水四氢呋喃(4.0 ml),滴加KHMDS溶液(1.0 M,1.0 ml),室温搅拌0.5 h,加入乙酸(1.0 eq.)淬灭反应,旋蒸蒸除溶剂,加入二氯甲烷和水,分出有机层,水层再用二氯甲烷萃取一次,有机相合并,依次用盐水和水洗涤,无水硫酸镁干燥,过滤浓缩,粗产物经硅胶柱层析(甲醇-乙酸乙酯),得类白色固体0.17 g,产率80%;
1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 3.7 Hz, 2H), 7.40 (s, 3H), 6.50 (s, 1H), 4.37 (s, 1H), 4.20 (s, 1H), 3.75 (d, J = 11.0 Hz, 1H), 3.47 (d, J = 10.9 Hz, 1H), 2.02 (d, J = 9.5 Hz, 1H), 1.86 (d, J = 9.4 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 173.6, 167.7, 135.5, 130.4, 128.3, 127.6, 63.3, 52.6, 51.4, 40.9。
实施例1所述的合成方法适用于实施例2~4。
实施例2:(1R,4R)-2-(4-甲氧基)苯甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
(1) (2S,4R)-1-(4-甲氧基)苯甲酰基-4-氨基脯氨酸甲酯的制备
合成方法与实施例1步骤(1)-(4)中所述方法类似;
(2)(1R,4R)-2-(4-甲氧基)苯甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
氮气保护下,将(2S,4R)-1-(4-甲氧基)苯甲酰基-4-氨基脯氨酸甲酯(100 mg,0.36 mmol)溶于无水四氢呋喃(2.0 ml),滴加KHMDS溶液(1.0 M,0.36 ml),室温搅拌0.5 h,加入乙酸(1.0 eq.)淬灭反应,旋蒸蒸除溶剂,加入二氯甲烷和水,分出有机层,水层再用二氯甲烷萃取一次,有机相合并,依次用盐水和水洗涤,无水硫酸镁干燥,过滤浓缩,粗产物经硅胶柱层析(甲醇-乙酸乙酯),得白色固体66 mg,产率75%;
1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 4.1 Hz, 2H), 7.32 (s, 2H), 6.42 (s, 1H), 4.50 (s, 1H), 4.20 (s, 1H), 3.90 (s, 3H), 3.75 (d, J = 8.4 Hz, 1H), 3.22 (d, J = 11.2 Hz, 1H), 2.00 (d, J = 10.1 Hz, 1H), 1.89 (d, J = 10.0 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 172.3, 170.6, 160.7, 128.3, 127.3, 63.2, 55.8, 53.3, 51.9, 39.9, 32.8。
实施例3:(1R,4R)-2-乙酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
(1)(2S,4R)-1-乙酰基-4-氨基脯氨酸甲酯的制备
合成方法与实施例1步骤(1)-(4)中所述方法类似;
(2) (1R,4R)-2-乙酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
氮气保护下,将(2S,4R)-1-乙酰基-4-氨基脯氨酸甲酯(500 mg,2.69 mmol)溶于无水四氢呋喃(15 ml),滴加KHMDS溶液(1.0 M,2.7 ml),室温搅拌0.5 h,加入乙酸(1.0 eq.)淬灭反应,旋蒸蒸除溶剂,加入二氯甲烷和水,分出有机层,水层再用二氯甲烷萃取一次,有机相合并,依次用盐水和水洗涤,无水硫酸镁干燥,过滤浓缩,粗产物经硅胶柱层析(甲醇-乙酸乙酯),得白色固体323 mg,产率78%;
1H NMR (400 MHz, CDCl3) δ 6.00 (s, 1H), 4.43 (s, 1H), 4.00 (s, 1H), 3.55 (d, J = 5.3 Hz, 1H), 3.52 (d, J = 10.3 Hz, 1H), 2.56 (s, 3H), 2.31 (d, J = 8.1 Hz, 1H), 1.80 (d, J = 8.9 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 177.5, 170.4, 65.3, 50.9, 41.6, 19.7。
实施例4:(1R,4R)-2-(叔丁氧基)甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
(1)(2S,4R)-1-(叔丁氧基)甲酰基-4-氨基脯氨酸甲酯的制备
合成方法与实施例1步骤(1)-(4)中所述方法类似;
(2) (1R,4R)-2-(叔丁氧基)甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
氮气保护下,将(2S,4R)-1-(叔丁氧基)甲酰基-4-氨基脯氨酸甲酯(3.20 g,13.1 mmol)溶于无水四氢呋喃(50 ml),滴加KHMDS溶液(1.0 M,13.2 ml),室温搅拌0.5 h,加入乙酸(1.0 eq.)淬灭反应,旋蒸蒸除溶剂,加入二氯甲烷和水,分出有机层,水层再用二氯甲烷萃取一次。有机相合并,依次用盐水和水洗涤,无水硫酸镁干燥,过滤浓缩,粗产物经硅胶柱层析(甲醇-乙酸乙酯),得白色固体1.95 g,产率70%;
1H NMR (400 MHz, CDCl3) δ 6.64 (bs, 1H), 4.35 (bs, 1H), 4.09 (s, 1H), 3.43 (d, J = 9.8 Hz, 1H), 3.22 (d, J = 8.0 Hz, 1H), 1.99 (d, J = 9.6 Hz, 1H), 1.81 (d, J = 7.6 Hz, 1H), 1.45 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 173.4, 153.6, 79.6, 60.1, 52.94, 49.6, 40.0, 27.1。
实施例5:(1R,4R)-2-苄基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
(1)(2S,4R)-4-羟基脯氨酸甲酯的制备
L-羟基脯氨酸(100 g, 0.76 mol)与甲醇(500 ml)混合,冰浴冷却下缓慢通入氯化氢气体,搅拌过夜。蒸除溶剂,加入二氯甲烷和水,加入碳酸钠调节pH至9-10间,分出有机层,水层再用二氯甲烷萃取一次;有机相合并,依次用盐水和水洗涤,无水硫酸镁干燥,过滤浓缩,得无色粘稠油状物104 g,产率94%。
(2)(2S,4R)-1-苄基-4-羟基脯氨酸甲酯的制备
(2S,4R)-4-羟基-脯氨酸甲酯(3.00 g,20.7 mmol)溶于氯仿(50 ml),加入三乙胺(4.0 ml,28.7 mmol)和苄溴(3.60 g,21.0 mmol),加热回流6 h,冷却,加入1 N氢氧化钠水溶液淬灭反应,有机层以水和食盐水洗涤,无水硫酸镁干燥,过滤浓缩,粗产物经硅胶柱层析(石油醚-乙酸乙酯),得无色粘稠油状物4.52 g,产率93%。
(3)(2S,4S)-1-苄基-4-羟基脯氨酸甲酯的制备
(2S,4R)-1-苄基-4-羟基-脯氨酸甲酯(7.7 g,32.7 mmol)溶于甲醇(100 ml),加入氢氧化钠(2.60 g,65 mmol),搅拌过夜。蒸除溶剂,加入少量水和浓盐酸调节pH至3-4,浓缩得(2S,4S)-1-苄基-4-羟基-脯氨酸固体粗产物。此固体溶于无水四氢呋喃(100 ml),在冰浴冷却下加入三苯基膦(17.17 g)和DEAD(7.7 ml),室温搅拌至反应完全。蒸除溶剂,加入乙酸乙酯和水,有机层经食盐水洗涤,无水硫酸镁干燥,过滤浓缩。所得固体溶于无水甲醇(50 ml),加入叠氮化钠(3.25 g,50 mmol),在40oC搅拌过夜,加入乙酸乙酯和饱和氯化铵水溶液,有机层经食盐水洗涤,无水硫酸镁干燥,过滤浓缩,粗产物经硅胶柱层析(石油醚-乙酸乙酯),得无色粘稠油状物4.24 g,产率55%。
(4)(2S,4R)-1-苄基-4-叠氮基脯氨酸甲酯的合成
方法与实施例1步骤(3)中所述方法类似;
(5)(2S,4R)-1-苄基-4-氨基脯氨酸甲酯的合成
方法与实施例1步骤(4)中所述方法类似;
(6)(1R,4R)-2-苄基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
氮气保护下,将(2S,4R)-1-苄基-4-氨基脯氨酸甲酯(460 mg,1.96 mmol)溶于无水四氢呋喃(6 ml),滴加KHMDS溶液(1.0 M,2.0 ml),室温搅拌0.5 h,加入乙酸(1.0 eq.)淬灭反应,旋蒸蒸除溶剂,加入二氯甲烷和水,分出有机层,水层再用二氯甲烷萃取一次。有机相合并,依次用盐水和水洗涤,无水硫酸镁干燥,过滤浓缩,粗产物经硅胶柱层析(甲醇-乙酸乙酯),得白色固体250 mg,产率63%;
1H NMR (400 MHz, CDCl3) δ 7.30-7.15 (m, 5H), 3.81 (d, J = 13.3 Hz, 2H), 3.45-3.38 (m, 2H), 3.20 (dd, J = 9.5, 1.5 Hz, 1H), 2.01 (dd, J = 9.5, 1.4 Hz, 1H), 1.83-1.73 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 173.5, 137.7, 127.6, 127.3, 126.1, 64.5, 57.4, 56.3, 54.1, 39.6。
实施例5所述的合成方法适用于实施例6~8。
实施例6:(1R,4R)-2-烯丙基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
(1)(2S,4R)-1-烯丙基-4-氨基脯氨酸甲酯的制备
合成方法与实施例5步骤(1)-(5)中所述方法类似;
(2)(1R,4R)-2-烯丙基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
氮气保护下,将(2S,4R)-1-烯丙基-4-氨基脯氨酸甲酯(200 mg,1.09 mmol)溶于无水四氢呋喃(4 ml),滴加KHMDS溶液(1.0 M,1.1 ml),室温搅拌0.5 h,加入乙酸(1.0 eq.)淬灭反应,旋蒸蒸除溶剂,加入二氯甲烷和水,分出有机层,水层再用二氯甲烷萃取一次,有机相合并,依次用盐水和水洗涤,无水硫酸镁干燥,过滤浓缩,粗产物经硅胶柱层析(甲醇-乙酸乙酯),得白色固体86 mg,产率52%;
1H NMR (400 MHz, CDCl3) δ 6.03 (s, 1H), 5.63-5.10 (m, 2H), 5.00 (s, 1H), 4.10-3.89 (m, 2H), 3.61 (d, J = 8.2 Hz, 1H), 3.34 (d, J = 9.2 Hz, 2H), 2.37 (dd, J = 10.3, 3.2 Hz, 1H), 1.80-1.75 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 172.5, 112.6, 110.8, 80.4, 60.6, 54.8, 50.9, 39.7。
实施例7:(1R,4R)-2-环己基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
(1)(2S,4R)-1-环己基-4-氨基脯氨酸甲酯的制备
合成方法与实施例5步骤(1)-(5)中所述方法类似;
(2)(1R,4R)-2-环己基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
氮气保护下,将(2S,4R)-1-环己基-4-氨基脯氨酸甲酯(350 mg,1.55 mmol)溶于无水四氢呋喃(8 ml),滴加KHMDS溶液(1.0 M,1.6 ml),室温搅拌0.5 h,加入乙酸(1.0 eq.)淬灭反应,旋蒸蒸除溶剂,加入二氯甲烷和水,分出有机层,水层再用二氯甲烷萃取一次。有机相合并,依次用盐水和水洗涤,无水硫酸镁干燥,过滤浓缩,粗产物经硅胶柱层析(甲醇-乙酸乙酯),得白色固体213 mg,产率71%;
1H NMR (400 MHz, CDCl3) δ 5.82 (s, 1H), 3.73-3.42 (m, 2H), 3.25 (d, J = 6.2 Hz, 1H), 3.10 (d, J = 14.3 Hz, 1H), 3.00 (s, 1H), 2.31-2.23 (m, 1H), 1.87-1.70 (m, 2H), 1.62-1.31 (m, 4H), 1.19-0.95 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 170.8, 65.9, 62.1, 54.8, 50.9, 39.7, 30.8, 24.6, 20.9。
实施例8:(1R,4R)-2-(1-苄基-4-哌啶基)-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
(1)(2S,4R)-1-(1-苄基-4-哌啶基)-4-氨基脯氨酸甲酯的制备
合成方法与实施例5步骤(1)-(5)中所述方法类似;
(2)(1R,4R)-2-(1-苄基-4-哌啶基)-6-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
氮气保护下,将(2S,4R)-1-(1-苄基-4-哌啶基)-4-氨基脯氨酸甲酯(150 mg,0.47 mmol)溶于无水四氢呋喃(5 ml),滴加KHMDS溶液(1.0 M,0.5 ml),室温搅拌0.5 h,加入乙酸(1.0 eq.)淬灭反应,旋蒸蒸除溶剂,加入二氯甲烷和水,分出有机层,水层再用二氯甲烷萃取一次。有机相合并,依次用盐水和水洗涤,无水硫酸镁干燥,过滤浓缩,粗产物经硅胶柱层析(甲醇-乙酸乙酯),得白色固体102 mg,产率76%;
1H NMR (400 MHz, CDCl3) δ 7.30-7.15 (m, 5H), 5.39 (s, 1H), 3.81-3.62 (m, 3H), 3.45-3.38 (m, 2H), 3.20 (dd, J = 9.5, 1.5 Hz, 1H), 2.41-2.10 (m, 5H), 1.83-1.73 (m, 2H), 1.53-1.28 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 170.8, 130.6, 126.4, 125.5, 110.3, 65.9, 62.1, 59.8, 54.8, 50.9, 39.7, 30.8, 24.6。
实施例9:(1R,4R)-3-羰基-2,5-二氮杂双环[2.2.1]庚烷的制备
将(1R,4R)-2-(叔丁氧基)甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷(1.50 g,7.07 mmol)与乙酸乙酯(100 ml)混合,冰浴冷却下缓慢加入氯化氢乙酸乙酯饱和溶液(20 ml),搅拌1 h后过滤,得到的固体加入二氯甲烷和碳酸氢钠水溶液,有机相经饱和食盐水洗涤,无水硫酸镁干燥,旋转蒸发得类白色固体0.50 g,产率63%。
1H NMR (400 MHz, DMSO-d 6) δ 6.64 (bs, 1H), 4.35 (bs, 1H), 4.09 (s, 1H), 3.30 (d, J = 9.8 Hz, 1H), 3.22 (bs, 1H), 3.15 (d, J = 8.0 Hz, 1H), 2.01 (d, J = 9.6 Hz, 1H), 1.77 (d, J = 7.6 Hz, 1H). 13C NMR (100 MHz, DMSO-d 6) δ 171.7, 78.9, 59.5, 51.1, 38.8。
实施例10:(1R,4R)-2-苄基-5-(叔丁氧基)甲酰基-2,5-二氮杂双环[2.2.1]庚烷的制备
在一个250毫升三口烧瓶中氮气保护下加入氢化锂铝(5.73 g, 0.15 mol)和无水四氢呋喃(100 ml),加热至回流后分批缓慢加入固体(1R,4R)-2-苯甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷(7.91 g, 0.037 mol),加毕回流搅拌1 h,反应液冷却后,分批加入十水合硫酸钠至反应完全,加入二碳酸二叔丁酯(8.0 g, 0.037 mol),继续搅拌1 h后过滤,滤饼以热四氢呋喃洗涤,滤液合并,旋转蒸发后经硅胶柱层析纯化,得无色油状物8.20 g,产率80%。
1H NMR (400 MHz, CDCl3) δ 7.29-7.22 (m, 4H), 7.18 (dd, J = 11.5, 4.6 Hz, 1H), 3.67 (d, J = 8.6 Hz, 2H), 3.41 (dd, J = 19.2, 12.1 Hz, 2H), 3.09 (dd, J = 10.4, 2.0 Hz, 1H), 2.88-2.76 (m, 1H), 2.67 (d, J = 9.7 Hz, 1H), 2.47 (d, J = 9.5 Hz, 1H), 1.80 (t, J = 8.8 Hz, 1H), 1.61 (dd, J = 24.9, 9.4 Hz, 1H), 1.39 (d, J = 2.9 Hz, 9H). 13C NMR (400 MHz, CDCl3) δ 154.6, 137.7, 127.5, 127.4, 126.1, 64.5, 57.4, 56.3, 54.1, 39.6, 27.1。
实施例11:(1R,4R)-2-甲基-5-(叔丁氧基)甲酰基-2,5-二氮杂双环[2.2.1]庚烷的制备
在一个250毫升三口烧瓶中氮气保护下加入氢化锂铝(1.71 g, 45 mmol)和无水四氢呋喃(50 ml),加热至回流后分批缓慢加入固体(1R,4R)-2-(叔丁氧基)甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷(2.25 g, 10.6 mmol),加毕回流搅拌1 h。反应液冷却后,分批加入十水合硫酸钠至反应完全。加入二碳酸二叔丁酯(2.31 g, 10.6 mmol),继续搅拌1 h后过滤,滤饼以热四氢呋喃洗涤,滤液合并,旋转蒸发后经硅胶柱层析纯化,得无色油状物1.55 g,产率69%。
1H NMR (400 MHz, CDCl3) δ 3.87 (d, J = 10.6 Hz, 1H), 3.55 (dd, J = 19.2, 10.1 Hz, 1H), 3.09 (dd, J = 10.4, 2.0 Hz, 2H), 2.88-2.76 (m, 2H), 2.47-2.17 (m, 3H), 1.80 (t, J = 8.8 Hz, 1H), 1.61 (dd, J = 24.9, 9.4 Hz, 1H), 1.39 (d, J = 2.9 Hz, 9H). 13C NMR (100 MHz, CDCl3) δ 155.1, 60.9, 57.4, 56.3, 54.1, 50.7, 39.6, 32.6, 27.0。
以上所述仅是本发明的优选实施方式。应当指出,对于本技术领域的普通技术人员,在不脱离本发明方法的前提下,还可进行若干改进和补充,这些可能的改进和补充也应视为本发明的保护范围。
Claims (9)
1.如通式I所示的2,5-二氮杂双环庚烷类化合物:
式中:R为-R1、-C(=O)R2或-C(=O)OR3;
其中R1为氢、或C1-C15的饱和或不饱和的取代基;R2为氢、或C1-C15的饱和、不饱和或芳香的取代基;R3为C1-C15的饱和、不饱和或芳香的取代基。
2.根据权利要求1所述的2,5-二氮杂双环庚烷类化合物,其特征在于:R1为C1-C15的饱和或不饱和的取代基,其为含碳环或杂环、或含直链或支侧链、或含杂原子的取代基。
3.根据权利要求1或2所述的2,5-二氮杂双环庚烷类化合物,其特征在于:R1为氢、甲基、乙基、丙基、异丙基、丁基、叔丁基、戊基、环戊基、己基、环己基、庚基、环己基甲基、辛基、壬基、癸基、烯丙基、苄基、4-甲氧基苄基、3-氟苄基、3-氯苄基、4-(1-苄基)哌啶基、3-(1-苄基)哌啶基。
4.根据权利要求1所述的2,5-二氮杂双环庚烷类化合物,其特征在于:R2为C1-C15的饱和、不饱和或芳香的取代基时,其为含碳环或杂环、或含直链或支侧链、或含杂原子的取代基。
5.根据权利要求1或4所述的2,5-二氮杂双环庚烷类化合物,其特征在于:R2为氢、甲基、乙基、丙基、异丙基、丁基、叔丁基、戊基、环戊基、己基、环己基、庚基、环己甲基、辛基、壬基、癸基、苯基、4-甲氧基苯基、3-氟苯基、3-氯苯基、乙烯基、1-甲基乙烯基、1-丙烯基、环戊基、环己基、2-噻吩基、3-噻吩基、2-吡啶基、3-吡啶基、4-吡啶基。
6.根据权利要求1所述的2,5-二氮杂双环庚烷类化合物,其特征在于:R3为C1-C15的饱和、不饱和或芳香的取代基为含碳环或杂环、或含直链或支侧链、或含杂原子的取代基。
7.根据权利要求1或6所述的2,5-二氮杂双环庚烷类化合物,其特征在于:R3为苄基、4-甲氧基苄基、4-氯苄基、甲基、乙基、丙基、丁基、叔丁基、烯丙基、环己基、苯基。
8.根据权利要求1、2、4或6所述的2,5-二氮杂双环庚烷类化合物,其特征在于:化合物选自
(1R,4R)-3-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-甲基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-乙基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-丙基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-环戊基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-环己基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-环己基甲基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-(1-苄基-4-哌啶基)-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-(1-苄基-3-哌啶基)-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-烯丙基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-苄基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-乙酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-丙酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-特戊酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-环戊甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-环己甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-苯甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-(4-甲氧基)苯甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-(甲氧基)甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-(乙氧基)甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-(烯丙氧基)甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-(苄氧基)甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷;
(1R,4R)-2-(叔丁氧基)甲酰基-6-羰基-2,5-二氮杂双环[2.2.1]庚烷。
9.权利要求1-8中任一项所述2,5-二氮杂双环庚烷类化合物在合成2,5-二氮杂双环[2.2.1]庚烷及其衍生物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410014704.4A CN103755710B (zh) | 2014-01-14 | 2014-01-14 | 一类2,5-二氮杂双环庚烷类化合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410014704.4A CN103755710B (zh) | 2014-01-14 | 2014-01-14 | 一类2,5-二氮杂双环庚烷类化合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103755710A true CN103755710A (zh) | 2014-04-30 |
CN103755710B CN103755710B (zh) | 2015-08-12 |
Family
ID=50523069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410014704.4A Expired - Fee Related CN103755710B (zh) | 2014-01-14 | 2014-01-14 | 一类2,5-二氮杂双环庚烷类化合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103755710B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106083862A (zh) * | 2016-06-08 | 2016-11-09 | 南京富润凯德生物医药有限公司 | 一种制备(1s,4s)‑2,5‑二氮杂二环[2.2.1]庚烷或[2.2.2]辛烷衍生物的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69010761T2 (de) * | 1989-05-11 | 1994-10-27 | Pfizer | Herstellung von diazabicyclischen Zwischenprodukten. |
WO2010011914A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Trpv4 antagonists |
CN102167700A (zh) * | 2010-02-25 | 2011-08-31 | 上海药明康德新药开发有限公司 | 3-三氟甲基-5-叔丁氧羰基-2,5-二杂双环[2.2.1]庚烷及制备方法 |
-
2014
- 2014-01-14 CN CN201410014704.4A patent/CN103755710B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69010761T2 (de) * | 1989-05-11 | 1994-10-27 | Pfizer | Herstellung von diazabicyclischen Zwischenprodukten. |
WO2010011914A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Trpv4 antagonists |
CN102167700A (zh) * | 2010-02-25 | 2011-08-31 | 上海药明康德新药开发有限公司 | 3-三氟甲基-5-叔丁氧羰基-2,5-二杂双环[2.2.1]庚烷及制备方法 |
Non-Patent Citations (2)
Title |
---|
JEAN-LOUIS REYMOND ET AL.: ""Synthesis and Nicotinic Receptor Activity of Chemical Space Analogues of N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-4-chlorobenzamide (PNU-282,987) and 1,4-Diazabicyclo[3.2.2]nonane-4-carboxylic Acid 4-Bromophenyl Ester (SSR180711)"", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
PHILIPG.HULTINAN ET AL.: ""Heterocyclic analogs of nucleosides: synthesis and biological evaluation of novel analogs of puromycin"", 《CAN.J.CHEM.》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106083862A (zh) * | 2016-06-08 | 2016-11-09 | 南京富润凯德生物医药有限公司 | 一种制备(1s,4s)‑2,5‑二氮杂二环[2.2.1]庚烷或[2.2.2]辛烷衍生物的方法 |
CN106083862B (zh) * | 2016-06-08 | 2018-07-13 | 南京富润凯德生物医药有限公司 | 一种制备(1s,4s)-2,5-二氮杂二环[2.2.1]庚烷或[2.2.2]辛烷衍生物的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103755710B (zh) | 2015-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7307723B2 (ja) | Pad阻害剤としてのイミダゾ-ピリジン化合物 | |
JP7346441B2 (ja) | 置換ピリジン及びピリミジン並びにglun2b受容体調節物質としてのそれらの使用 | |
CN102089307A (zh) | 作为激酶抑制剂的吡咯并吡啶 | |
CA2425067A1 (en) | Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors | |
AU2018375308A1 (en) | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | |
KR102470497B1 (ko) | 신경계 및 신경변성 질환을 치료하기 위한 5,7-디히드로-피롤로-피리딘 유도체 | |
CA3143105A1 (en) | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators | |
JP2011518127A (ja) | ヒスタミンh3受容体アンタゴニストとしてのテトラヒドロナフチリジンおよびそれらのアザ誘導体 | |
CN103547569A (zh) | N-取代内酰胺化合物的制造方法 | |
AU2021241879A1 (en) | Monoacylglycerol lipase modulators | |
CN105294536A (zh) | 一种制备3-亚氨基异吲哚啉酮类化合物的方法 | |
CN105367427B (zh) | 手性1,2‑二胺类化合物及其制备方法和应用 | |
CN101712645A (zh) | 一种(2r,4r)-4-取代-2-哌啶羧酸化合物的制备方法及其中间体 | |
Liao et al. | A concise and divergent approach to radicamine B and hyacinthacine A3 based on a step-economic transformation | |
CN104262225A (zh) | 一种3-氨基吡咯烷化合物及其合成方法和用途 | |
CN103755710B (zh) | 一类2,5-二氮杂双环庚烷类化合物及其应用 | |
CN103755686A (zh) | 具有抗血小板聚集活性的哌啶基取代5-羟色氨酸衍生物 | |
AU2021350335A1 (en) | Cyclobutyl amide monoacylglycerol lipase modulators | |
TW202222797A (zh) | 吡唑并[1,5-a]吡啶類化合物及其製備方法和應用 | |
CN105237492A (zh) | 一种依折麦布中间体的合成方法 | |
Zhou et al. | Flexible syntheses of 5, 8-disubstituted indolizidine poisonous-frog alkaloids via a Michael-type conjugate addition | |
CA3066986A1 (en) | Dihydro-pyrrolo-pyridine derivatives | |
CN103864771A (zh) | 一种利伐沙班的制备方法 | |
Li et al. | First way of enantioselective synthesis of moxifloxacin intermediate | |
Sengoku et al. | Extremely high regio-and stereoselective C–C bond formation of substituted γ-hydroxylactams: synthesis of macronecines based on their structural duality |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150812 Termination date: 20210114 |